跳至主要内容
临床试验/KCT0001058
KCT0001058已完成未知

An Open Label, Randomized, 2-Sequence, Multiple-Dose Cross-Over Study to Investigate the Drug-Drug Interaction of Sevikar and Crestor in Healthy Adult Volunteers

Daewoong Pharmaceutical0 个研究点目标入组 32 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
32

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
19(Year) 至 55(Year)(—)
性别
Male

入选标准

  • 1.Healthy male subjects aged 19 - 55 years
  • 2.A body mass index in the range 19 - 27 kg/m2
  • 3.Willingness to participate during the entire study period
  • 4.Written informed consent after being fully informed about the study procedures

排除标准

  • 1.Any past medical history of hepatic, renal, gastrointestinal, respiratory, endocrine, psychiatric, neurologic, haemato-oncologic or cardiovascular disease
  • 2.History of clinically significant drug hypersensitivity
  • 3.Use of medication within 7 days before the first dose
  • 4.Heavy drinker (>140 g/week)
  • 5.Whole blood donation during 60 days before the study
  • 6.Judged not eligible for study participation by investigator

研究者

发起方
Daewoong Pharmaceutical

相似试验

尚未招募
不适用
An Open-label, Randomized, Single- and Multiple-dose, Phase 1 Clinical Trial to Evaluate the Pharmacokinetics of Iron and Safety/Tolerability after the Oral Administration of KP-01 in Korean Adult with Iron Deficiency (with or without anaemia)
KCT0007911Seoul National University Hospital24
尚未招募
1 期
An Open Label, Randomized, Two-Period, Two-Sequence, Single Oral Dose, Crossover Bioequivalence Study of ECOXIA (120 mg) of the Government Pharmaceutical Organization, Thailand with ARCOXIA (120 mg) of Frosst Iberica, S.A., Spain in Normal, Healthy, Adult Human Subjects under Fasting ConditionsHealthy male and female subjectsBioequivalence fed conditions
TCTR20211104001The Government Pharmaceutical Organization30
已完成
不适用
An open-label, randomized, two-period, two-sequence crossover, single-center trial to assess the bioequivalence of a single dose of 600 IU of freeze-dried r-hLH (Luveris®) versus a single 600 IU dose of the liquid formulation of Luveris® in the Pre-Filled Pen, administered subcutaneously (SC) in pituitary suppressed healthy premenopausal female subjects.vrouwelijke ovruchtbaarheidfemale infertilitypituitary hormone deficiency
NL-OMON37820Merck Sharp & Dohme (MSD)54
已完成
不适用
A randomized, open-label, two-period, two-sequence, single-dose, cross-over study to compare the pharmacokinetics, safety, and tolerability of the auto injector and pre-filled syringe of SB4 in healthy male subjects.
NL-OMON45442Samsung Bioepis Co., Ltd.46
已完成
1 期
A study to investigate the effect of enzyme inhibition on the bodily processing of RO6953958 in healthy participantson-respiratory sleep disturbances in people with neurodevelopmental disorders (NDDs)Nervous System Diseases
ISRCTN10164855Roche (Switzerland)16